Skip to main content

Table 3 Univariable Cox-regression analysis for clinical parameters as predictors of mortality following coronary intervention

From: Prognostic irrelevance of plaque vulnerability following plaque sealing in high-risk patients with type 2 diabetes: an optical coherence tomography study

  HR (95% CI) p
Age (per year) 1.11 (1.04–1.18) 0.001
Sex (male) 0.65 (0.28–1.51) 0.320
ACS at presentation (presence) 0.99 (0.41–2.41) 0.983
CV risk profile
 BMI (per kg/m2) 0.91 (0.82–1.00) 0.059
 Waist circumference (per 10 cm) 0.94 (0.68–1.30) 0.718
 Hypertension (presence) 0.94 (0.28–3.17) 0.923
 Hyperlipidemia (presence) 0.70 (0.30–1.66) 0.704
 Total cholesterol (per 10 mg/dl) 1.05 (0.95–1.16) 0.313
 LDL-c (per 10 mg/dl) 1.07 (0.94–1.21) 0.311
 HDL-c (per 10 mg/dl) 1.43 (1.02–1.99) 0.036
 Triglycerides (per 10 mg/dl) 0.98 (0.92–1.04) 0.447
 Active smoking (presence) 0.99 (0.37–2.66) 0.981
 Pack years (per 10 py) 0.95 (0.79–1.16) 0.637
 Family history of CAD (presence) 0.35 (0.14–0.89) 0.351
 Previous CAD (presence) 1.99 (0.88–4.52) 0.099
 Previous PCI (presence) 1.93 (0.85–4.41) 0.118
 Previous CABG (presence) 2.29 (0.31–17.1) 0.418
 hsCRP (per 10 mg/dl) 1.06 (0.93–1.22) 0.375
 GFR (per 10 mg/dl/1.73 m2) 0.49 (0.27–0.90) 0.020
Other comorbidities
 COPD (presence) 1.30 (0.44–3.48) 0.638
Diabetes severity and therapy
 Diabetes duration (per year) 1.03 (0.99–1.06) 0.125
 Diabetic polyneuropathy (presence) 2.94 (1.29–6.68) 0.010
 Diabetic retinopathy (presence) 1.90 (0.75–4.82) 0.178
 HbA1c (per 1%) 1.34 (0.92–1.97) 0.131
 Insulin (presence) 3.44 (1.45–8.13) 0.005
 Metformin (presence) 0.40 (0.17–0.90) 0.028
 Sulfonylamides (presence) 0.73 (0.25–2.16) 0.575
 Incretins (presence) 2.11 (0.87–5.14) 0.100
Other relevant medication
 Aspirin (presence) 1.21 (0.16–8.96) 0.854
 Statin (presence) 0.54 (0.24–1.24) 0.149
 ACE or ARBi (presence) 0.76 (0.31–1.85) 0.547
 Beta-blocker (presence) 0.52 (0.22–1.24) 0.142
  1. ACS acute coronary syndrome, BMI body mass index, CAD coronary artery disease, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, GFR glomerular filtration rate, COPD chronic obstructive pulmonary disease, ACE angiotensin converting enzyme, ARB angiotensin receptor blocker